Abbott Laboratories: A Dividend Aristocrat With A Compelling Valuation And Return Potential

Dividend Yield Theorist10.15K FollowersFollow5ShareSavePlay(11min)CommentsSummaryAbbott Laboratories has declined over 16% since my last review, which was previously rated a HOLD, as the valuation was a little rich.The acquisition of Exact Sciences adds a solid piece to a company with a long, proven track record.The segments were kind of a mixed bag in the most recent earnings report, and I'll be monitoring the struggling areas to see where they might go.My valuation model points to ABT trading for a decent discount, while also boasting a strong future return potential.

Getty Images Investment Thesis Abbott Laboratories appears to be trading for an attractive discount at this time, while offering a return potential north of 15%. The company recently closed a large acquisition that should drive strong growth moving forward, as well asThis article was written byDividend Yield Theorist10.15K FollowersFollowI have a masters degree in Analytics from Northwestern University and a bachelors degree in Accounting. I have worked in the investment arena for over 10 years starting as an analyst and working my way up to a management role. Dividend investing is a personal hobby and I look forward to sharing my thoughts with the Seeking Alpha community.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in ABT over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.